Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 28, Issue 13, Pages 2280-2285
Publisher
American Society of Clinical Oncology (ASCO)
Online
2010-03-30
DOI
10.1200/jco.2009.27.2757
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure
- (2017) G. D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of sorafenib in elderly patients (pts) ≥65 years: A subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America
- (2017) R. M. Bukowski et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
- (2009) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
- (2009) Youjin Je et al. LANCET ONCOLOGY
- Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study
- (2009) Giancarlo Agnelli et al. LANCET ONCOLOGY
- Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study
- (2009) M. Kozloff et al. ONCOLOGIST
- Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis
- (2008) David Chu et al. ACTA ONCOLOGICA
- Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis
- (2008) Xiaolei Zhu et al. ACTA ONCOLOGICA
- Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients
- (2008) Shobha Rani Nalluri et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
- (2008) Manuela Schmidinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
- (2008) Matthew H. Kulke et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice
- (2008) T. MEYER et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- CONSORT for reporting randomised trials in journal and conference abstracts
- (2008) Sally Hopewell et al. LANCET
- Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
- (2008) Shenhong Wu et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started